Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.52 |
| ▸ | MEN1 | O00255 | 3/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | TYR | P14679 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | CASP6 | P55212 | 1/20 | 0.45 |
| ▸ | CASP3 | P42574 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | ACHE | P22303 | 4/20 | 0.41 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19835276 | 0.90 | CASP3 (0.51) | KMT2AMEN1KDM4EHPGDMAPT | |
| SCHEMBL19835651 | 0.87 | CASP3 (0.46) | KMT2AMEN1KDM4EHPGDMAPT | |
| SCHEMBL19835815 | 0.86 | MALT1 (0.51) | KMT2AMEN1KDM4EHPGDTYR | |
| SCHEMBL19835248 | 0.84 | CASP3 (0.44) | KMT2AMEN1KDM4EHPGDMAPT | |
| SCHEMBL19835406 | 0.83 | MALT1 (0.51) | KMT2AMEN1KDM4EHPGDTYR | |
| SCHEMBL19835809 | 0.82 | CASP3 (0.56) | KMT2AMEN1HPGDLMNAL3MBTL1 | |
| SCHEMBL19835505 | 0.82 | HTT (0.50) | KMT2AMEN1KDM4EHPGDTYR | |
| SCHEMBL2418409 | 0.80 | KMT2A (0.55) | KMT2AMEN1KDM4EHPGDMAPT | |
| SCHEMBL30116791 | 0.80 | KMT2A (0.55) | KMT2AMEN1KDM4EHPGDMAPT | |
| SCHEMBL19835813 | 0.80 | CHRM5 (0.48) | KMT2AMEN1CASP3NPSR1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10662156-B2 | Guanidine derivative and medical use thereof | TORAY INDUSTRIES, INC. (JP) | 2020-05-26 | — | — | US | disclosed |
| US-10662156-B2 | Guanidine derivative and medical use thereof | TORAY INDUSTRIES, INC. (JP) | 2020-05-26 | — | — | US | disclosed |
| US-20190233376-A1 | GUANIDINE DERIVATIVE AND MEDICAL USE THEREOF | TORAY INDUSTRIES, INC. (JP) | 2019-08-01 | — | — | US | disclosed |
| US-20190233376-A1 | GUANIDINE DERIVATIVE AND MEDICAL USE THEREOF | TORAY INDUSTRIES, INC. (JP) | 2019-08-01 | — | — | US | disclosed |
| EP-3495348-A1 | GUANIDINE DERIVATIVE AND USE THEREOF FOR MEDICAL PURPOSES | Toray Industries, Inc. (JP) | 2019-06-12 | — | — | EP | disclosed |
| WO-2018021520-A1 | GUANIDINE DERIVATIVE AND USE THEREOF FOR MEDICAL PURPOSES | 東レ株式会社 | 2018-02-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190233376-A1 | GUANIDINE DERIVATIVE AND MEDICAL USE THEREOF | MALT1, GUCY1A1, GUCY1B1 | KMT2A 2465/4885MEN1 1551/4885KDM4E 1362/4885 |
| US-10662156-B2 | Guanidine derivative and medical use thereof | MALT1, GUCY1A1, GUCY1B1 | KMT2A 2465/4885MEN1 1551/4885KDM4E 1362/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.